geranyl farnesyl acetate
Trade name: Gefarnate
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
4
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00787254)
Timeline
Indications
Mechanism of action
- Farnesyl diphosphate synthaseSUBSTRATE
FDPS substrate
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC(=O)OC/C=C(\C)CCC=C(C)C- Mol. weight
- 400.65 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105085 ↗
Also known as
- da-688
- da-688
- dixnalate
- gefarnate
- gefarnate
- gefarnate
- gefarnate
- gefarnate
- gefarnate
- gefarnate
- gefarnate
- gefarnyl
- geranyl farnesylacetate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03610321 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2018 | Harbin Medical University |
| NCT01051388 | Phase 3 | Aug 1, 2008 | Kobe University, Translational Research Informatics Center, Kobe, Hyogo, Japan |
| NCT00762359 | Phase 3 | May 1, 2007 | Takeda |
| NCT00787254 | Phase 3 | Apr 1, 2007 | Takeda |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 2 | 1 | 2007 |
| Harbin Medical University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Kobe University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Translational Research Informatics Center, Kobe, Hyogo, Japan | Academic/Hospital | 1 | 1 | 1 | 2008 |
4 organizations
Page 1 / 1